Medical Device and Healthcare Industry Trends — 2026-07-21
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
The South Korean medical device industry is at a turning point driven by regulatory shifts and innovation. The FDA's move to ease oversight on AI and wearables, combined with Samsung's enhanced AI health watches, is accelerating global competition. Meanwhile, local challenges like medical professional training controversies and barriers to clinical adoption for digital healthcare remain critical hurdles.
Medical Device and Healthcare Industry Trends — 2026-07-21
Today's Top 5 Headlines
- Samsung Electronics to launch Galaxy Watch 9 with enhanced AI health features on July 22, intensifying the wearable medical device race.
- Medical community warns against aesthetic medical device companies providing training and sales to traditional Korean medicine doctors and dentists; collaborations are being re-evaluated.
- FDA releases guidelines to ease oversight on AI medical devices and wearables, granting regulatory exemptions for low-risk Clinical Decision Support (CDS) tools.
- UpDoc Inc. secures the first FDA approval for an SaMD featuring patient-facing LLMs, opening a new path for clinical AI developers.
- South Korean medical professionals highlight the difficulties of clinical adoption for digital healthcare, citing persistent challenges in scaling business after technology and licensing.
Samsung Electronics
- What's happening: Positioning the Galaxy Watch 9 as an AI health companion, with an official launch scheduled for July 22.
- Key figure: Significant strengthening of wearable health features to rebuild market competitiveness.
- Implication: As Samsung's watch lineup pivots to AI-based clinical support, competition in the wearable medical device space is expected to intensify with LG and local medical device manufacturers. The FDA's easing of wearable regulations provides a favorable environment for Korean companies to expand globally.
Medical Device Manufacturers (Aesthetic Sector)
- What's happening: Strong backlash from the medical community regarding the practice of aesthetic device companies providing sales and training to Korean medicine doctors and dentists.
- Key figure: Major medical associations have begun a full review of their cooperation with these companies.
- Implication: Collective monitoring by the medical community against regulatory-evading sales is intensifying, which is likely to force aesthetic device companies to overhaul their business models. Long-term, this could lead to a redefinition of the scope for medical device permits.
MFDS · Policy · Regulation
MFDS abolishes 'sales suspension grace period' for GMP violations
- Details: Total abolition of the 'sales suspension grace period' for violations of Manufacturing and Quality Management Standards for in vitro diagnostic medical devices; immediate sales suspension to be enforced.
- Target: In vitro diagnostic (IVD) manufacturers.
- Effective Date: Enforced after March 2026 (for new products failing to meet standards before the expiration of the GMP validity period).
- Industry Impact: Stricter regulatory compliance obligations for medical device manufacturers will increase quality costs and necessitate adjustments to delivery schedules. Barriers to entry for small-scale manufacturers are expected to rise.
Discussions on separating manufacturing and item permits for medical devices
- Details: Following the enactment of the Special Act on Regulatory Support for Biopharmaceutical CDMOs, there is a growing need to separate manufacturing permits from item permits for medical devices.
- Target: All medical device manufacturers and distributors, particularly small and medium-sized Contract Manufacturing Organizations (CMOs).
- Effective Date: The Biopharmaceutical CDMO Special Act takes effect December 31, 2026; separate standards for medical devices are to be discussed later.
- Industry Impact: Expected to lead to greater transparency in manufacturing processes and clearer accountability, potentially causing structural reorganization of the medical device industry. Existing integrated manufacturers should consider business diversification.
Digital Health · AI Medicine
-
FDA eases oversight on AI medical devices and wearables: The FDA released guidance exempting low-risk Clinical Decision Support (CDS) and wearables with wellness functions from regulation—a development South Korean AI medical device firms can leverage for U.S. entry.
-
UpDoc Inc. receives FDA approval for patient-facing LLM SaMD: On June 25, clinical AI firm UpDoc received FDA approval for an SaMD featuring a patient-facing Large Language Model (LLM), offering a new roadmap for developers and a reference model for Korean SaMD firms.
-
Deepening challenges for South Korean digital healthcare in clinical settings: Industry leaders agree that even with proven technology and clinical evidence, sustaining businesses after entering the institutional market remains difficult due to a lack of reimbursement standards, medical staff resistance, and insurance uncertainty.
Global MedTech Context
-
FDA's AI/wearable deregulation trend: The expansion of U.S. exemptions for low-risk devices will accelerate health wearable entry for major tech firms like Samsung and LG, while improving accessibility to the U.S. market for domestic startups.
-
Opening of FDA approval paths for clinical AI developers: UpDoc's approval for patient-facing LLM SaMD provides a template for AI medical device companies like Lunit and Vuno to build and submit data according to U.S. regulatory standards earlier.
-
Wearables, robotic surgery, and clinical AI as key 2026 tasks: Humanoid surgical robots, Google SensorFM wearable AI, and the issue of clinical skill decay are prompting a review of AI governance in health systems.
Investment · M&A · IPO Trends
No new South Korean medical device or healthcare investments or M&A deals have been announced in the last 24 hours. However, global demand for AI wearables and SaMD investments is rising, and South Korean companies are expected to accelerate preparations for U.S. market entry.
Today's Insight
The FDA's deregulation of AI and wearables is expected to act as a catalyst, reshaping the global competitive landscape for the South Korean medical device industry. Samsung's AI health watch launch and UpDoc's SaMD approval suggest rapid growth in the wearable and SaMD markets. Domestically, strengthening regulations on aesthetic devices and resolving hurdles for digital healthcare's clinical entry have emerged as mid-term challenges. Companies and policy innovations that overcome these will likely define the next growth phase for Korean MedTech.
This Week's Checkpoints
- Schedule for the Ministry of Food and Drug Safety (MFDS) to announce detailed standards for separating manufacturing and item permits.
- Progress on discussions regarding the application of the Biopharmaceutical CDMO Special Act (effective Dec 31, 2026) to medical devices.
- Analysis of GMP compliance status and cost impacts for major medical device companies (aesthetic, diagnostic).
Reader Action Items
- Medical device manufacturers: Audit quality control processes in preparation for the abolition of the sales suspension grace period regarding GMP violations.
- AI/SaMD developers: Analyze the FDA's new low-risk SaMD deregulation criteria (UpDoc case) and reassess the classification of your own products.
- Investors/Entrepreneurs: Identify teams capable of overcoming clinical entry barriers (reimbursement/insurance) in Korean digital healthcare and review 'overseas-first' strategies leveraging the ease of U.S. regulations.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
